PHIO vs PMI Comparison

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.